Catalyst Pharmaceuticals (CPRX) Non-Current Deffered Revenue (2011 - 2013)
Catalyst Pharmaceuticals (CPRX) posted Non-Current Deffered Revenue of $19131.0 for Q4 2013, down 4.54% on a QoQ basis from $20040.0 in Q3 2013, and down 12.56% year-over-year from $21878.0 in Q4 2012.
Catalyst Pharmaceuticals (CPRX) Non-Current Deffered Revenue (2011 - 2013) Analysis & Trends
Catalyst Pharmaceuticals' Non-Current Deffered Revenue history runs 3 years deep, the most recent figure standing at $19131.0 for Q4 2013.
- Quarterly Non-Current Deffered Revenue fell 12.56% year-over-year to $19131.0 in Q4 2013, while the trailing twelve-month figure through Dec 2013 was $19131.0 (down 12.56% YoY) and the FY2013 annual result came in at $19131.0, down 12.56% from the prior year.
- Non-Current Deffered Revenue was $19131.0 for Q4 2013 at Catalyst Pharmaceuticals, down from $20040.0 in the prior quarter.
- Across five years, Non-Current Deffered Revenue topped out at $22004.0 in Q2 2012 and bottomed at $9518.0 in Q4 2011.
- A 3-year average of $19212.7 and a median of $20653.0 in 2013 frame the typical range for Non-Current Deffered Revenue.
- Annual changes were most pronounced in 2012 — Non-Current Deffered Revenue jumped 129.86% — and 2013, when it fell 12.56%.
- Catalyst Pharmaceuticals' Non-Current Deffered Revenue stood at $9518.0 in 2011, then soared by 129.86% to $21878.0 in 2012, then retreated by 12.56% to $19131.0 in 2013.
- Business Quant data shows CPRX's Non-Current Deffered Revenue at $19131.0 in Q4 2013, $20040.0 in Q3 2013, and $20653.0 in Q2 2013.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 225.10 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Catalyst Pharmaceuticals | 3.85 Bn | 3.09 Bn | 134.92 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2013 | 19,131.00 |
| Sep 30, 2013 | 20,040.00 |
| Jun 30, 2013 | 20,653.00 |
| Mar 31, 2013 | 21,265.00 |
| Dec 31, 2012 | 21,878.00 |
| Jun 30, 2012 | 22,004.00 |
| Dec 31, 2011 | 9,518.00 |